Altrius Capital Management Inc Sells 15,005 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Altrius Capital Management Inc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,402 shares of the biopharmaceutical company’s stock after selling 15,005 shares during the period. Altrius Capital Management Inc’s holdings in Gilead Sciences were worth $4,379,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in GILD. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter worth about $29,000. Finally, Crews Bank & Trust purchased a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $111.99 on Friday. The firm has a market capitalization of $139.57 billion, a PE ratio of 302.68, a PEG ratio of 0.71 and a beta of 0.18. The business’s 50-day simple moving average is $96.98 and its 200 day simple moving average is $89.65. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $112.57. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Morgan Stanley upped their price objective on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.08.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 293,356 shares of company stock worth $29,166,240. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.